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Breast cancer (BC) is a heterogeneous disease that is classically driven by the estrogen receptor 
(ER), progesterone receptor (PR) and human epithelial growth factor receptor 2 (EGFR2/HER2) 
signaling pathways. Triple negative breast cancer (TNBC), is a lethal subtype of invasive BC 
tumors that are ER-, PR- and HER2-. A subtype of TNBC is claudin low (CL). Dysregulation of 
claudin proteins disrupts tight junctions, consequently inducing the epithelial-to-mesenchymal 
transition (EMT) in cancers. This leads to enhanced motility and metastasis. Patients with CL 
TNBC have worse prognosis than patients with other BC subtypes.  
PVT1 is a long noncoding RNA (lncRNA) transcribed from the 8q24 genomic locus that has 
been implicated in multiple cancers including BC. Amplification of the 8q24 gene locus is a 
common event in many malignant diseases and is associated with poor clinical outcomes. 
Although previous research has implicated PVT1 as an important player in BC, the underlying 
molecular mechanisms of PVT1 in CL TNBC were previously unknown.  
We assessed PVT1 expression in BC, and we observed that PVT1 exon 9 is significantly 
upregulated in MDA MB 231 cells (claudin low) and significantly downregulated in MDA MB 
468 cells (claudin high), in comparison to T47D (ER+). We have confirmed that claudin 
expression, specifically, claudins 1, 3, 4 and 7, are significantly higher in MDA MB 468 cells and 
significantly lower in MDA MB 231 cells. Knockdown of PVT1 exon 9 expression in the MDA 
MB 231 cell line, led to a significant reduction in migration when compared to cells transfected 
with a control scramble siRNA, indicating that PVT1 exon 9 regulates migration in CL TNBC. 
 Interestingly, we observed that claudin 4 expression, and not claudins 1, 3 and 7, was increased 
in cells where PVT1 exon 9 was knocked down when compared to the control cells. This indicates 
that PVT1 exon 9 regulates claudin 4 protein stability in CL TNBC. We also assessed the 
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expression of EMT markers (vimentin, fibronectin, and E-cadherin) in MDA MB 231 cells. We 
observed no changes in EMT markers when PVT1 exon 9 is knocked down; however, our data 
suggests that EMT markers are more highly expressed in MDA MB 231 cells in comparison to 
MDA MB 468 cells. Taken together, our data indicate that PVT1 exon 9 regulates claudin 
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4.1. Background  
 
Breast cancer is the most commonly diagnosed non-skin cancer, and second leading cause 
of cancer mortality, in U.S. women (1, 2). The lifetime risk of a breast cancer diagnosis for a 
woman in the U.S. is 13%, while the risk of death is approximately 2.6%. According to the 
American Cancer Society, in 2020, an estimated 276,480 new cases of invasive breast cancer 
will be diagnosed in women, of which close to 42,170 women will die from the disease. 
Presently, it has been reported that there are 3.5 million breast cancer survivors in the U.S. (1).
 Breast cancer is classified according to the expression of three specific molecular markers; 
estrogen receptor (ER), progesterone receptor (PR) and human epithelial growth factor 
receptor 2 (EGFR2/HER2) (3). Approximately 80% of breast cancers are ER+ (4), while 55-
65% are PR+ (5). The ER and PR, which both exist as 2 different isoforms, are critical 
predictive and prognostic markers for breast cancer management  (4, 5). Tumors that are ER+/ 
PR+ respond better to endocrine therapy than tumors that are ER-/PR+, or ER+/PR- and 
especially ER-/PR- (5).  
ER and PR status are closely associated with clinical outcomes. Patients with ER-/PR+, 
ER+/PR-, or ER-/PR- status experience higher risk of mortality (6) and higher histological 
grade than patients who are ER+/PR+ (7). EGFR2/HER2 amplification is observed in 25-30% 
of breast cancers and acts as a driver for aggressive tumors (8). Although overexpression of 
EGFR2/HER2 is used as a prognostic marker in breast cancer management, it is also associated 
with a poor prognosis and drug resistance (9). Moreover, breast cancer molecular subtypes are 
classified into intrinsic subtypes, each with a distinct gene expression pattern that can have 
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important implications for therapeutic strategies and treatment efficacy (10).  
The most commonly categorized subgroups are luminal A, which accounts for 30-40% of 
all invasive breast cancer, luminal B, or HER2- which accounts for 20-30% of all invasive 
breast cancer, and HER2+, which accounts for 12-20% of all invasive breast cancer (5). 
Patients with luminal A subtype experience a more favorable prognosis, while prognosis of 
patients with a luminal B subtype is more intermediary (5). 
Luminal subtypes are ER+ and are therefore more responsive to hormonal therapy, less 
aggressive and associated with better prognosis. HER2+ subtypes experience the opposite 
outcomes (3, 5, 10). Another intrinsic subtype of breast cancer, which accounts for 10-15% of 
all breast cancer cases (11), is triple negative breast cancer (TNBC). TNBC describes invasive 
tumors that are ER-, PR- and HER2- (12) and can further be subdivided into additional 
subtypes: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), 
mesenchymal stem-like/claudin low (MSL/CL) and luminal androgen receptor (LAR) (13).
 TNBC disproportionately affects premenopausal African American (AA) women. These 
women are more likely to experience higher grade characterization, higher mitotic index, later 
stage diagnosis and higher mortality rate compared to white women (3, 14, 15). The molecular 
complexity of TNBC contributes to the difficulties associated with successful treatment. The 
loss of target receptors is the primary reason why hormonal therapy is not beneficial for TNBC 
patients.  
Current approaches for managing TNBC include surgery and chemotherapy either 
individually, or in combination (16). Claudin low TNBC has the worst clinical outcomes when 
compared to other breast cancer subtypes (13). Furthermore, the underlying molecular  
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mechanism regulating claudin status is not fully understood. An investigation into the factors 
that mediate negative clinical outcomes in claudin low TNBC may provide insight into how 
they can be exploited for better prognostication and therapeutic strategies, consequently 
leading towards better clinical outcomes. 
4.2. PVT1  
 
Protein coding genes are estimated to account for approximately 2% of the human genome 
(17), while the remaining 98% were thought to be “junk DNA”. As it turns out, these non-
protein coding DNA can be transcribed into RNA, or non-coding RNAs (ncRNAs) (18). 
ncRNAs can be categorized according to their size: small ncRNAs and long ncRNAs 
(lncRNAs). Small ncRNAS, such as small nucleolar RNAs (snoRNAs), Piwi-associated RNAs 
(piRNAs) and microRNAs (miRNAs), are transcripts that are less than 200 bp, while lncRNAs 
are transcripts that are greater than 200 bp (19). 
 LncRNAs, which makes up the majority of ncRNAs, have been reported to play a 
significant regulatory role in various biological processes including transcription (20), 
translation (21), DNA repair (22) and chromatin remodeling (23). Aberrant expression of 
lncRNAs have been observed in multiple diseases (24-26), including cancer (27), and may 
serve as an important biological marker for diagnosis and targeted therapeutic strategies. 
Previous studies have demonstrated that amplification of the 8q24 gene locus is a common 
event in many malignant diseases (28). 
 Plasmacytoma variant translocation 1 (PVT1), a long noncoding RNA (lncRNA) that is 
transcribed at the 8q24 gene locus, has been demonstrated to play an oncogenic role in multiple 




 PVT1 gene is a large locus that is greater than 30 kb (20), and contains several exons, namely 
exons 1a, 1b, 1c, 2, 3a, 3b, 4a, 4b, 5, 6, 7, 8, 9 and 10 (28). Additionally, PVT1 encodes multiple 
alternatively spliced lncRNA as well as six annotated microRNAs: miR-1204, miR-1205, miR-
1206, miR-1207-3p, miR-1207-5p and miR-1208 (31). Approximately 53 kb upstream of 
PVT1 is the oncogene MYC (32). 
  
Figure 1: PVT1 structure and transcripts. PVT1 is located downstream of the MYC gene on 
chromosome 8q24. The PVT1 exon involved in this project is highlighted yellow: PVT1 exon 9. 
PVT1 also encodes 6 microRNAs: miR-1204, miR-1205, mir-1206, miR-1207-3p, miR-1207-
5p and miR-1208. 
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4.3.  PVT1 and breast cancer 
 
LncRNAs have been reported to play a significant role in various biological processes. The 
involvement of lncRNAs in tumorigenesis has been well recorded. More specifically, studies 
have demonstrated that lncRNAs are involved in the regulatory mechanisms of various 
processes by acting as critical regulators of gene expression (33). There is much evidence that 
demonstrates lncRNA, PVT1, involvement in regulating different cellular processes, which 
can ultimately promote malignancies, including angiogenesis (34), cell cycle progression (35), 
proliferation and apoptosis (36).  
PVT1 amplification is associated with many clinicopathological characteristics in breast 
cancer (29). Studies have demonstrated that PVT1 promotes proliferation and tumorigenesis. 
Tang et. al. reported that PVT1 promotes proliferation in TNBC via a PVT1/KLF5/b-catenin 
pathway. PVT1 binds to, and stabilizes transcription factor KLF5. This then leads to b-catenin 
upregulation, which is associated with poor prognosis in breast cancer patients. Conversely, 
down regulation of PVT1 led to the rapid degradation of KLF5, which resulted in an inhibition 
of proliferation and tumor growth (37).  Wang et. al. reported that upregulation of transcription 
factor SOX2 is correlated with PVT1 expression. SOX2 binds to the promoter of PVT1, 
activating its transcription, which then promotes cell growth and invasion in breast cancer (38).
 PVT1 also regulates apoptosis (29) and metastasis (39) in breast cancer. One of the most 
vital processes in metastatic cancer is the epithelial-to-mesenchymal transition (EMT). In one 
study, PVT1 has been shown to affect EMT in triple negative breast cancer. E-cadherin and 
vimentin are 2 major EMT markers. Knockdown of PVT1 expression, using siRNAs, resulted 
in the upregulation of E-cadherin, and the down regulation of vimentin and N-cadherin. 
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This result suggests that downregulation of PVT1 inhibits EMT (40). Wang et. al. reported that 
PVT1 was overexpressed in both breast cancer tissue and cells via a SOX2 facilitated manner. 
Downregulation of PVT1 inhibited EMT, therefore blocking cancer progression (38). 
 PVT1-derived transcripts have been demonstrated to promote breast tumorigenesis as a 
well. miR-1207 has been shown to be distinctly upregulated in breast cancer in young women 
(41). Aberrant expression of miR-1207-5p has been shown to promote proliferation, colony 
formation and cell cycle progression in breast cancer, by targeting transcription factor, STAT-
6, and downregulating its expression. miR-1207-5p has also been shown to promote 
chemoresistance in TNBC by targeting Leucine	zipper	tumor	suppressor	gene	1	(LZTS1). 
Consequently, this led to a decrease in apoptosis and cell growth arrest, which is induced by 
Taxol. Conversely, combined treatment of Taxol with antagomir-1207-5p upregulated 
expression of pro-apoptotic gene Bax, and downregulated expression of anti-apoptotic genes 
Bcl-2 and p-Akt (42). Liu et. al. reported that miR-1204 promotes proliferation and EMT by 
targeting the vitamin D receptor gene (VDR) and modulating its expression (39). VDR is a 
transcription factor that is involved in cell growth and differentiation in both normal, and 
tumor, breast tissue  (43). Future research should be conducted to further explore the 
involvement of PVT1 transcripts in breast cancer, and even other malignancies.  
4.4. Tight Junctions (TJs) and tumorigenesis  
 
Epithelial and endothelial cell-cell adhesion are mediated through multi-protein junctional 
complexes, which among other things, are responsible for maintaining a cells’ architectural 
structure. There are four main types of intercellular junctions; gap junctions, adherens 
junctions (AJs) and tight junctions (TJs), which are located in the apical most region of the 
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cell, and desmosomes, which are located towards the basal region of the cell (44, 45). AJs and 
desmosomes primarily contribute to the mechanical adhesions between neighboring cells, 
while TJs are linked to maintaining cellular homeostasis, as well as many other cellular 
functions (46).  
TJs are multifunctional complexes composed of both transmembrane and peripheral 
proteins that connect cells via homophilic and heterophilic interaction (44, 45). They are 
comprised of a network of strands that encircle a cell creating a boundary that separates the 
apical domain of the cell from the basal domain. Consequently, this separation forms a “gate”, 
or para-cellular diffusion barrier, which regulates permeability and a “fence”, or 
intramembrane diffusion barrier, which limits apical-basolateral diffusion (47, 48). In addition 
to their role in intercellular adhesion and acting as a semipermeable barrier, TJs functions as a 
barrier to cellular motility (49), can recruit adaptor proteins which offer anchorage, and 
cytosolic partners that assemble into signaling complexes (44). TJ signaling occurs in a 
bidirectional manner. Signals transduced from inside the cell towards TJs guide their assembly 
and regulate their functions. Signals transmitted from TJs into the cell regulate gene 
expression, including cell proliferation and cell differentiation (47). TJ complexes are involved 
in various other cellular functions including maintaining cellular polarity, cell cycle and vesicle 
trafficking (44, 45, 47, 48, 50, 51). Currently, there are over 40 TJ proteins that has been 
topologically characterized into at least four major transmembrane proteins that constitutes 
epithelial TJs; occludin, claudins, the coxsackievirus and adenovirus receptor (CAR), and  
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members of the junctional adhesion molecule family (JAM) (44, 45). 
The involvement of TJs in cancer biology is associated with dysfunctional signal 
transduction pathways that regulate cell-cell interactions, in other words, loss of cell polarity 
and growth control (52). Aberrant expression of TJ proteins disrupts normal physiological 
function, which could lead to pathological consequences. Many studies have demonstrated the 
dysregulation of TJ proteins in cancer (53-57). JAM and CAR, for example, are proteins are 
type I transmembrane proteins, and members of the immunoglobulin superfamily (58, 59) with 
various functionalities including cell adhesion including platelet activation (60, 61), 
angiogenesis (62) and cell migration (63, 64).  
Previous work has demonstrated a novel link between JAM-A overexpression and reduced 
survival of breast cancer patients (65), contrastingly, it was reported that downregulation of 
JAM-A occurs early in renal cancer and increases renal cancer cell migration (66). CAR 
overexpression is associated with a lower survival rate in oral squamous cell carcinoma (67) 
and is associated with a higher grade of malignancy in breast cancer (68). Contrastingly, CAR 
has been reported to act as a metastatic suppressor in lung cancer (69) and a tumor suppressor 
in gastric cancer (70), therefore downregulation of CAR expression can have serious clinical 
implications.  
4.5.  Claudins in cancer  
 
Named after the Latin word 'claudere’ which means to close, claudins (CLDNs) are a 
family of TJ proteins that consists of 27 members (71). Ranging in size between 20-34 kDa, 
these tetraspan proteins contains an amino and carboxyl-terminal cytoplasmic domain (72), as 
well as 2 extracellular loops which are critical for maintaining TJ function (73). CLDNs, via  
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the PDZ-binding motifs along their carboxyl-terminus, can interact directly with multiple 
signaling pathways and PDZ domain-containing cytoplasmic TJ-associated proteins such as 
ZO-1, ZO-2, ZO-3, PATJ and MUPPI (45, 74, 75). CLDNs are extremely tissue or cell specific. 
Most tissues or cells express CLDNs in various combinations or ubiquitously, while others 
may express a single CLDN (76).  
Arguably the most important constituent of TJs, CLDN functions primarily involves 
maintaining cellular polarity, signaling (77), as well as regulating and maintaining paracellular 
permeability via a paracellular barrier (47, 48) or paracellular channel (71). CLDNs, through 
use of both mechanisms, regulate the transport of solutes between cells, including charged and 
uncharged ions, and small molecules (71). Various studies demonstrate compelling evidence 
of CLDNs and their role in tumorigenicity. Aberrant expression of CLDNs have been well 
documented whereby both loss and gain of function have been associated with multiple cancers 
including prostate (78), colorectal (79, 80), liver (78, 80), pancreatic (80), lung (81), cervical 
(82), gastric (83), ovarian (84, 85) and breast (86, 87). In particular, CLDNs 1, 3, 4 and 7 are 
among the most frequently dysregulated of the CLDN family members (52, 88).  
The discrepancy in the expression of CLDNs, in combination or individually, can vary 
according to tumor type. In one study, it was reported that epithelial tumors can be 
distinguished from other tumors, including lymphoid and soft tissue tumors, or tumors of a 
higher grade, due to the specific differential expression of CLDNs 1, 2, 3, 4, 5 and 7 (89). 
Downregulation of CLDNs impede barrier functions by amplifying the influx of nutrients and 
growth factors needed by cancerous cells (71). CLDN7 under expression have been reported  
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in invasive breast (90), colon (91) and prostate cancer (92), as well as esophageal (93) and 
renal cancer (94) Similarly, under expression of CLDN1 have been reported in invasive breast 
(95), prostate (92), liver (96) and colon cancer (91).  
Altered expression of CLDN1 has been demonstrated to be associated with higher tumor 
grade (97), recurrence (87) and metastasis and invasion (98). Contrastingly, many studies have 
demonstrated that overexpression of CLDNs are also associated with cancer development and 
progression. Upregulation of CLDNs also affect barrier function and increase paracellular 
permeability (71). Overexpression of CLDN3 and CLDN4, for example, is a common process 
in several malignancies including pancreatic, uterus, thyroid, stomach, and breast (78). In 
ovarian cancer, CLDN3 and CLDN4 are among the most highly upregulated genes (99). 
Moreover, studies showed that increased expression of these CLDNs were found in advanced 
staged tumors (100), and may cause increased cell survival, motility and invasion (101).
 Overall, the altered expression of CLDNs is dichotomous. This further supports that these 
TJs are indeed tissue and cell specific. There are many studies that demonstrate the role they 
play in tumorigenicity, however the underlying mechanisms and their biological significance 
in cancer remains unclear. 
4.6. Claudin 4 and breast cancer 
 
Claudin 4 (CLDN4), is one of the most frequently dysregulated of the CLDN family 
members (52, 88), and has been reported to be involved in various biological processes 
including EMT (102), metastasis and invasion (103), and epigenetic modulation (104). The 
clinicopathological associations of CLDN4 in breast cancer is well documented. Patients with 
CLDN4 overexpression experience high tumor grade and poor prognosis, as well as shorter 
disease-free survival. Additionally, it was reported that there is an association between ER 
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status and CLDN4 expression. CLDN4 expression was significantly higher in tumors that were 
ER- (105, 106).  
Some studies have demonstrated how CLDN4 can be a useful prognostic marker in breast 
cancer (107, 108).  Kulka et. al. reported that CLDN4 expression was significantly higher in 
basal-like carcinomas, as opposed to the other tumor groups (grades 1-3). In fact, tumors of 
lower grades, specifically grades 1 and 2, had decreased or absent expression of CLDN4 (109). 
Contrastingly, Kolokytha et. al. reported that enhanced expression of CLDN4 in luminal breast 
cancers were linked to poor outcomes, while overexpression of CLDN4 in TNBC was 
associated with favorable outcomes. According to the study, tumors which overexpressed 
CLDN4 displayed a less aggressive phenotype (105). The conflicting results concerning 
CLDN4 expression in breast cancer is a clear indication that future studies are warranted. In 
an in vivo study carried out by Ma et. al., mice that were implanted with MCF-7 cells where 
CLDN4 was knocked down had significantly smaller tumors than tumors from the control 
group. Additionally, it was reported that CLDN4 upregulation, via methylation status, 
increased cell proliferation and migration of MCF-7 cells, while inhibiting apoptosis. (110). 
Taken together, these results support that CLDN4 promotes breast tumorigenesis.
 Vasculogenic mimicry (VM) refers to an important de novo process in which aggressive 
tumors undergo in the absence of endothelial cells. This process can occur independent of 
angiogenesis to establish an oxygen and nutrient supply via the formation of vessel-like 
channels (111). Cui et. al. reported that CLDN4 is required for VM formation. More 
specifically, upregulation of CLDN4 induced VM formation, while downregulation of CLDN4 




was more prevalent in more aggressive breast cancer cells than cells that were less aggressive 
(112). 
4.7. Project rationale 
 
We’ve previously reported that alternatively spliced transcripts of PVT1 were differentially 
expressed in prostate cancer. More specifically, PVT1 exon 9 were overexpressed in prostate 
cancer tissue taken from men of African Ancestry (moAA) (113). This suggests that PVT1-
derived transcripts in prostate cancer tend to include one or more of these 3 exons in moAA. 
PVT1 exon 9 expression was significantly higher in prostate cancer cell lines derived from 
moAA when compared to cell lines derived from Caucasian men. PVT1 exon 9 expression was 
elevated in more aggressive cell lines, in comparison to cell lines that were less aggressive 
(114). Taken together, these results suggest that PVT1 exon 9 is potentially associated with a 
more aggressive prostate cancer phenotype. Moreover, an in vivo study carried out by our 
group demonstrated that overexpression of PVT1 exon 9 plays a significant role in prostate 
cancer initiation and progression (115), thus establishing an oncogenic role for PVT1 exon 9 
in prostate cancer.  
PVT1 amplification is a common occurrence in many malignancies including breast 
cancer, and is associated with poor survival rate among patients (29, 37, 114). Many studies 
have demonstrated a critical functional role for PVT1 in breast cancer (29, 40), however the 
underlying molecular mechanisms associated with PVT1 transcripts in breast cancer are not 
well understood. In this study, we were interested in investigating the role of PVT1 exon 9 
play in breast cancer. We hypothesized that one or more of these transcripts may be correlated  
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with PVT1 function in breast cancer. 
4.8.  Experimental workflow 
 
A panel of 5 breast cancer cell lines, with distinct molecular subtyping (ie: luminal A, 
luminal B, HER2+ and triple negative), were used to assess the expression levels of PVT1 
exon 9. Total RNA was isolated from each cell line, followed by cDNA synthesis. Using 
custom-designed primers, all mRNA expressions for PVT1 exon 9 were determined via RT-
qPCR. PVT1 exon 9 was significantly overexpressed in claudin low (CL) triple negative breast 
cancer (TNBC) cell line, MDA MB 231, and significantly under expressed in claudin high 
(CH) TNBC cell line MDA MB 468.  
PVT1 exon 9 expression was knocked down in CL TNBC cell line MDA MB 231, 
following transfection with a highly efficient patent-protected siRNA (siPVT1 exon 9). A 







































































Table 1: Characterization of 5 breast cancer cell lines  
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 expression was done via total RNA isolation, cDNA synthesis and RT- qPCR. A functional assay 
was carried out to determine the regulatory role this transcript plays in TNBC.  
PVT1 exon 9 was overexpressed in CH TNBC cell line MDA MB 468, following 
transfection with a plasmid vector expressing PVT1 exon 9. A corresponding empty vector was 
used as a control. Verification of mRNA expression was done via total RNA. 
 
 isolation, cDNA synthesis and RT-qPCR. 
CLDNs 1, 3, 4 and 7 are among the most frequently dysregulated of the CLDN family members 
(52, 88). The discrepancy in the expression of CLDNs, in combination or individually, can vary 
according to tumor type. Following knock down, and overexpression, of PVT1 exon 9 in CL 
TNBC cell line MDA MB 231 and CH TNBC MDA MB 468, respectively, mRNA expression for 
Table 2: Primer sequences used for RT-qPCR 
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CLDNs 1, 3, 4 and 7 were determined using RT-qPCR. Western blotting was done to examine the 
protein expression CLDNs. 
Studies show that dysregulation of CLDN proteins disrupts tight junctions consequently 
inducing the epithelial-to-mesenchymal transition (EMT) in cancers, resulting in enhanced 
motility (122). Following knock down, and overexpression, of PVT1 exon 9 in CL TNBC cell line 
MDA MB 231 and CH TNBC MDA MB 468, respectively, western blotting was carried out to 
assess the expression of EMT markers. 
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5. Materials and Methods: 
 
5.1.  Cell Lines and Cell Culture 
 
A panel of 5 breast cancer cell lines were used to assess the expression of PVT1 exon 9. 
MDA MB 231, MDA MB 468, T47D and MCF-7 cells were kind gifts from Dr. Jill Bargonetti 
(City University of New York, Hunter College) and BT474 from Dr. Brian Zeglis (City 
University of New York, Hunter College). MDA MB 231, MDA MB 468, T47D and MCF-7 
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% 
FBS and 0.5% penicillin/streptomycin. Trypsinization of cells occurred using 0.05% trypsin 
when cells were 70-80% confluent. BT474 was maintained in F12/DMEM (GIBCO), 
supplemented with 10% FBS and 1% penicillin/streptomycin. Trypsinization of cells occurred 
using 0.25% trypsin when cells were 70-80% confluent. All cell lines were cultured in a 5% 
CO2, 37 °C atmosphere. 
5.2.  Transfection of siRNAs 
 
MDA MB 231 cells were grown in 6-well plates until they have reached 90-100% 
confluency. According to the manufacturer’s instructions, cells were transfected with 10 nM 
of PVT1 exon 9 siRNA (siPVT1 exon 9) (Forward: 5’ ACCUAUGAGCUUUGAAUAA 3’; 
Reverse: 5’ UUAUUCAAAGCUCAUAGGU 3’) (Sigma, St. Louis, MO, USA), or a non-
targeting scramble control (siScramble) (Forward: 5’ CUCACUACCGUCGACCCCA 3’; 
Reverse: 5’ UGGGGUCGACGGUAGUGAG 3’) (Sigma, St. Louis, MO, USA) using 
Lipofectamine RNAiMAX (Thermo Fisher Scientific Inc.; Wilmington, DE, USA). siRNAs 
and Lipofectamine were diluted in Opti-MEM(ThermoFisher Scientific Inc.; Wilmington, DE, 
USA). Following transfection, cells were incubated for 24 h in a 5% CO2, 37 °C atmosphere 
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before being harvested, or migration assay. 
5.3. RNA extraction and RT-q PCR 
 
At 70-75% confluency, total RNA was extracted from cells in a 60 x 15 mm tissue culture 
dish, using the RNeasy Mini Kit (QIAGEN, Hilden Germany, cat#: 74104) according to the 
manufacturers’ instructions. RNA concentration was measured using the spectrophotometer 
NanoDropTM 2000 (Thermo Fisher Scientific, Inc.). cDNA was synthesized from 1 µg of 
RNA using QuantiTect reverse transcription kit (Qiagen, Germany, cat# 205311). 
Amplification reactions were performed in 25 µL reaction volume using SYBR Green PCR 
master mix (Life Technologies, Grand Island, NY, USA cat# 4309155), cDNA template and 
0.4 µM final concentration for primers. Primers used in this study were composed of the 
following oligonucleotide sequences listed in Table 2. Using the Quantifect Studio System 
(Applied Biosystems), relative expression of messenger RNA (mRNA) for each sample was 
assessed in quadruplicates in at least 3 independent experiments, and quantified via the 
comparative cycle threshold (∆∆ Ct) method and normalized to GAPDH mRNA expression. 
5.4.  Protein extraction and Immunoblotting  
 
Whole cell extracts were obtained using a cocktail of RIPA lysis buffer (VWR Life 
Science, cat# N653-100ML) supplemented with 10 x protease inhibitor and 100 mM of phenyl 
methylsulfonyl fluoride (PMSF) (Amresco, cat# M145-5G). Protein concentration was 
quantified via the Bradford Assay using the Bio-Rad Protein Assay Dye Reagent  
Concentrate (Biorad, cat# 500-0205). For Western blot analysis, 50 µg of protein were resolved 
by 15% SDS-PAGE gels and subsequently transferred onto nitrocellulose membranes. 
Membranes were blocked in 5% BSA or 5% milk in TBS-T for 1 hour at room temperature, 
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incubated overnight at 4 °C in primary antibodies, washed in 1 x TBS-T, incubated with 
secondary antibodies for 2 hours, washes with 1 x TBS-T and imaged using the LI-COR 
Odyssey CLx imager with infrared fluorescence. The primary antibodies used were directed 
against Claudin 1 (13050-1-AP), Claudin 4 (16195-1-AP) and Claudin 7 (10118-1-AP) 
(Proteintech, Rosemont, IL, USA), Claudin 3 (341700; Invitrogen, Waltham, MA, USA), 
GAPDH (5174S; 1:1000; Cell Signaling, MA, USA), alpha-tubulin (sc-32293; 1:1000; Santa 
Cruz Biotechnology, TX, USA). The secondary antibodies used were anti-mouse (925-32210; 
1:15,000; LI-COR, Lincoln, NE, USA) and anti-rabbit (925-32211; 1:15,000; LI-COR, 
Lincoln, NE, USA). 
5.5.  Migration Assay 
 
1 x 105 MDA MB 231 cells were grown in a 6-well tissue culture plate until 90-100% 
confluency. Cells were transfected with siRNA, or siScramble, and incubated at 5% CO2, 37 
°C for 24 h. Following transfection, and using a sterile 200 µL pipet tip, wounds were made to 
cell monolayer in each well. Wounded cells were washed with 1X PBS and incubated with 
media. Images of scratched areas were taken at 10X magnification using the Motic AE30 
Inverted microscope.   
5.6.  Statistical Analysis 
 
Data from at least 3 independent experiments were presented as mean ± standard error of 
the mean (S.E.M). Statistical significance was assessed using a two-tailed 





6.1.  Expression of claudins 1, 3, 4 and 7 in TNBC. 
 
To assess the expression of claudins 1, 3, 4 and 7 in each cell line, we performed total RNA 
extraction, cDNA synthesis and real-time quantitative polymerase chain reaction (RT-qPCR).  
 
We observed that claudins 1, 3, 4 and 7 are downregulated in the MDA MB 231 TNBC cell 
line, when compared to the MDA MB 468 TNBC cell line. (Fig. 2).    
6.2. Expression of PVT1 exon 9 is upregulated in claudin low TNBC 
To assess the expression of PVT1 exon 9 in each cell line, we performed total RNA extraction, 
cDNA synthesis and real-time quantitative polymerase chain reaction (RT-qPCR). We  
  
Figure 2: Claudins 1, 3, 4 and 7 expression in MDA MB 468 and MDA MB 231 cells. 
Claudin 1 (A), claudin 3 (B), claudin 4 (C) and claudin 7 (D) expression were assessed 




observed that PVT1 exon 9 is overexpressed in CL MDA MB 231 TNBC cell line when 






















6.3.  PVT1 exon 9 regulates migration in claudin low TNBC 
 
To determine the regulatory roles of PVT1 exon 9 in TNBC, an siRNA study was 
conducted. We knocked down the expression of PVT1 exon 9 in MDA MB 231 cells and 
performed wound healing assays (Fig. 2). The relative expression of PVT1 exon 9 was verified 
by qPCR. Assessment of the migratory capabilities of cells are based on the rate in which the 
wound closes. Pictures were taken at 0h, 4h, 24h and 28h. We observed that cells in which 
PVT1 exon 9 was knocked down were less migratory than their scramble control counterpart. 
siPVT1 exon 9 cells exhibited a 20% decrease in migration in comparison with siScramble 
cells (Fig 4). The decrease of migration in MDA MB 231 cells is statistically significant (p- 
Figure 3: PVT1 exon 9 expression in MDA MB 468 and MDA MB 231 cells. PVT1 exon 
and 9 expression was assessed using qPCR in MDA MB 231 and MDA MB 468. Expression 
was normalized against GAPDH. Experiment was carried out at least 3 times.  
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value: 0.01). This suggests that PVT1 exon 9 may be involved in regulating cell motility in 
TNBC. 
6.4. PVT1 exon 9 regulates claudin 4 expression in claudin low TNBC 
To determine if PVT1 exon 9 was regulating claudin expression, total RNA was isolated 
to assess CLDN expression, at a transcriptional level, following knockdown of PVT1 exon 9 
in MDA MB 231 cells. RT-qPCR was used to qualitatively assess CLDN mRNA expression. 
We observed that knockdown of PVT1 exon 9 in MDA MB 231 does not significantly affect 
CLDN mRNA expression when compared to the control (Fig 5). Next, proteins were isolated 
to assess CLDN expression at a translational level. A western blot was used to assess CLDN 
protein expression when PVT1 exon 9 is knocked down in MDA MB 231 cells. We did not  
  
Figure 4: PVT1 exon 9 regulates migration in MDA MB 231 cells. (A) Wound healing 
migration assays were performed on MDA MB 231 cell line. Cells were transfected once 
confluent. After 24 hours wounds were made and measured between 0 hour and 28 hours. (B) 
siRNA Transfection. Relative expression of PVT1 Exon 9 in MDA MB 231 based on 2 
independent experiments. (C) Migration quantification; n=3 
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observe any significant change in expression for CLDNs 1, 3 and 7 when PVT1 exon 9 is  
knocked down. Interestingly, we observed a re-expression of CLDN4 in MDA MB 231 when 
PVT1 exon 9 expression is knocked down (Fig 6). These results suggest that PVT1 exon 9 is 
regulating claudin 4 expression in TNBC. 
6.5.  PVT1 exon 9 does not regulate EMT in TNBC 
 
EMT is a critical process that occurs in many malignancies (102), and PVT1 has been 
shown to be involved in EMT induction (40). To investigate if PVT1 exon 9 transcript may be 













E-cadherin and fibronectin, in MDA MB 231 cells. We observed no changes in EMT markers 
when PVT1 exon 9 is knocked down; however, our data suggests that EMT markers are more  
  
Figure 5: PVT1 exon 9 does not regulate claudin transcription in MDA MB 231 cells. 
Claudin 1 (A), claudin 3 (B), claudin 4 (C) and claudin 7 (D) expression were assessed 
following knock down of PVT1 exon 9 in MDA MB 231 cell line. Normalized against GAPDH; 
(n=3).  
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highly expressed in MDA MB 231 cells in comparison to claudin high MDA MB 468 TNBC 











































Figure 6: PVT1 exon 9 regulates claudin 4 expression in MDA MB 231 cells. MDA MB 231 
were transfected with siPVT1 exon 9 specific siRNAs for 24 hours. Western blotting was 
performed using antibodies against claudin 1, claudin 3, claudin 4 and claudin 7. Loss of PVT1 




Breast cancer remains the second leading cause of cancer related death in U.S. women (1, 2). 
Although much progress has been made in breast cancer treatment, patients with TNBC continue 
to have poor prognosis (14). CL TNBC has the worst prognosis. Additionally, there are no effective 
treatments presently available to manage this breast cancer subtype (13). Therefore, it is imperative 
that efforts are made towards understanding the molecular mechanisms which regulate CLDN 
expression as it would facilitate the development of novel therapeutic strategies. PVT1 has already 
been demonstrated to play a role in breast tumorigenesis (38, 39). However, the specific long non-
coding transcripts that are important in breast cancer are unclear. Moreover, to our knowledge, 
PVT1 regulation of CLDN expression has not been previously studied  
With a total of approximately 12 exons, the PVT1 gene encodes several alternatively spliced 
lncRNA transcripts. Differential expression of these transcripts in breast cancer has not been 
previously investigated. The purpose of this study was to investigate the association between breast 
tumorigenesis and PVT1 transcripts containing exon 9. In this study, we demonstrated that PVT1 
exon 9 may play an important regulatory role in TNBC. Our group has previously reported that 
the transcript from exon 9, PVT1 exon 9, was differentially expressed in prostate cancer. More 
specifically, PVT1 exon 9 was overexpressed in prostate cancer tissue taken from men of African 
Ancestry (moAA) (113). This finding suggests that alternatively spliced transcripts of PVT1, 
including transcript containing PVT1 exon 9, may be associated with increased risk of cancer 
among moAA. Additionally, PVT1 exon 9 expression was significantly higher in prostate cancer 
cell lines derived from moAA when compared to cell lines derived from Caucasian men, and the 
elevated expression was associated with an aggressive phenotype (114). In an in vivo study,  
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overexpression of PVT1 exon 9 induced malignant transformation of prostate epithelial cells 
and increased proliferation and migration in these cells (115). The aforementioned studies 
established an oncogenic role for PVT1 exon 9 in prostate cancer; however, the significance 
of PVT1 exon 9 in breast cancer was not previously investigated.  
 In breast cancer cell lines, each varying based on molecular characteristics, we observed 
that PVT1 exon 9 was significantly overexpressed in CL MDA MB 231 TNBC cells, and 
significantly under-expressed in CH MDA MB 468 TNBC cells, when compared to T47D 
cells. Consequently, we used claudin low MDA MB 231 as a model for PVT1 exon 9 
overexpression, and claudin high MDA MB 468 as a model for PVT1 exon 9 under-expression.   
We observed that MDA MB 231 cells transfected with siPVT1 exon 9 were less migratory 
when compared to cells that were transfected using siScramble. These results suggest that 
overexpression of PVT1 exon 9 increases the migratory capacity of TNBC cells, and that loss 
of PVT1 exon 9 expression may have a protective role by making cells less migratory. Cancer 
cell migration is a characteristic of metastasis in cancer patients and is associated with poor 
prognosis (39). Further studies are necessary in order to elucidate the underlying mechanisms 
by which this regulatory process occurs. Moreover, additional in vitro and in vivo functional 
assays, and molecular analysis, should be carried out in order to better understand the role of 
PVT1 exon 9 in breast tumorigenesis. 
CLDNs 1, 3, 4 and 7 are among the most frequently dysregulated of the CLDN family 
members (52, 88). The difference in the expression of CLDNs is tissue and cell specific, which 
could signify a difference in their function based on their localization and expression. Previous 
studies reported that lncRNAs act as critical regulators of gene expression (33). 
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This is in keeping with our observation that PVT1 exon 9 is overexpressed in CL MDA MB 
231 TNBC cells and under expressed in CH MDA MB 468 TNBC cells. Consequently, we 
speculate that PVT1 exon 9 may be regulating claudin expression either at a post-
transcriptional level, a post-translational level, or indirectly.  
In keeping with previous reports, we have confirmed the CLDN expression profile. Our 
results showed no significant change in CLDN mRNA expression. Consequently, this result 
suggests that PVT1 exon 9 may not be regulating claudin expression at a transcriptional level 
in claudin low MDA MB 231. It may be that PVT1 exon 9 may be interacting with CLDN 
proteins directly, or indirectly, to regulate their expression. 
Our data demonstrate that PVT1 regulates CLDN expression. We observed that when 
PVT1 exon 9 is knocked down there is no change in protein expression for CLDNs 1, 3 and 7, 
however, we did observe a re-expression of CLDN4 in CL MDA MB 231 TNBC cells. 
LncRNAs are known to interact with proteins to regulate their stability, or ubiquitination (123). 
Since knockdown of PVT1 expression led to an increase in CLDN4 protein expression, it is 
plausible that PVT1 exon 9 regulates CLDN4 protein expression by regulating its 
ubiquitination. Consequently, PVT1 overexpression may regulate CLDN4 downregulation by 
regulating its ubiquitination. Overexpression of CLDN4 is reported to have unfavorable 
clinical outcomes (109), interestingly, the results suggest that re-expression of CLDN4 in CL 
MDA MB 231 TNBC cells is associated with a reduction in migration. 
Evidence supports that abnormal expression of CLDNs and PVT1 induce the epithelial-to- 
mesenchymal transition (EMT) in many cancers, resulting in enhanced cellular motility (122). 
We assessed the expression of EMT markers E-cadherin, vimentin and fibronectin (data not 
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shown). We observed no changes in the expression of EMT markers when PVT1 exon 9 is 
knocked down. However, our data suggests that EMT markers are more highly expressed in 
CL MDA MB 231 TNBC cells in comparison to CH MDA MB 468 TNBC cells. Additionally, 
it also supports that MDA MB 231 cells are more mesenchymal than MDA MB 468 cells. 
Overall, this result suggests that PVT1 exon 9 may not regulate EMT in TNBC. 
In conclusion, this study demonstrated that PVT1 exon 9 may have a regulatory role in 
claudin low TNBC. Knock down of PVT1 exon 9 resulted in the re-expression of CLDN4 
protein expression, without any significant change in CLDN4 mRNA expression. This 
suggests that PVT1 exon 9 regulates CLDN4 expression at a translational, or post-translational 
level. Additionally, we demonstrated that over expression of PVT1 exon 9 is associated with 
increased migration in CL MDA MB 231 cells. Consequently, PVT1 exon 9 may regulate 







8. Future Directions: 
 
Claudin low tumors have much worse outcomes than other subtypes (13) therefore future 
studies are critical to further understand the underlying molecular mechanism of PVT1 exon 9 in 
TNBC. Our results suggest that PVT1 exon 9 is regulating CLDN4 expression, however the 
mechanisms remain unclear. One strategy is to understand how PVT1 exon 9 may be interacting 
with CLND4. For example, is PVT1 exon 9 directly binding to CLDN4 to regulate its expression, 
or is PVT1 exon 9 regulating CLDN4 expression via downstream targets? Furthermore, it is 
important to investigate the overexpression of PVT1 exon 9 in MDA MB 468. PVT1 exon 9 is 
significantly under-expressed in MDA MB 468. In vitro studies to assess the significance of the 
transient overexpression of PVT1 exon 9 in a claudin high model should be carried out. These 
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